Market revenue in 2023 | USD 427.6 million |
Market revenue in 2030 | USD 992.4 million |
Growth rate | 12.8% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66% in 2023. Horizon Databook has segmented the Italy circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in disease burden, unmet needs of patients, and shortage of generics are expected to drive the branded generics market in Italy. There is an opportunity for branded generic manufacturers to introduce more products, as the country is focusing on reducing healthcare expenses.
In EU5, Italy had the smallest generic market. This market is highly influenced by Italy’s independent pharmacies. Established local players dominate the branded generics market in the country by influencing through local sales force and maintaining good relationships with physicians. Such factors are expected to drive branded generics’ market growth in Italy.
According to World Bank, in 2019, over 23% of the population in Italy was aged over 65, and this percentage is expected to grow in the coming years. The increasing geriatric population is expected to boost the demand for treatment of age-related disorders, such as Alzheimer’s and Parkinson’s disease, thereby driving demand for branded generics in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into Italy circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account